Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial-Reference-Cited by-同舟云学术

Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial

Published:2023-04 Issue:4 Volume:10 Page:e230-e243
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Mahomed Sharana,Garrett Nigel,Capparelli Edmund V,Osman Farzana,Mkhize Nonhlanhla N,Harkoo Ishana,Gengiah Tanuja N,Mansoor Leila E,Baxter Cheryl,Archary Derseree,Yende-Zuma Nonhlanhla,Samsunder Natasha,Carlton Kevin,Narpala Sandeep,McDermott Adrian B,Doria-Rose Nicole A,Moore Penny L,Morris Lynn,Abdool Karim Quarraisha,Mascola John R,Abdool Karim Salim S

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference30 articles.

1. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016–2021: actions for impact,2021

2. Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study;de Oliveira;Lancet HIV,2017

3. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV;Bares;Curr Opin HIV AIDS,2022

4. Clinical trials of broadly neutralizing monoclonal antibodies for HIV prevention: a review;Mahomed;J Infect Dis,2021

5. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape;Moore;Nat Med,2012

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical trials and recent progress in HIV vaccine development;Functional & Integrative Genomics;2024-08-28

2. Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines;Cell Reports Medicine;2024-08

3. Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial;BMC Infectious Diseases;2024-07-20

4. Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial Acronym: PedMAb1;2024-07-19

5. Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial;PLOS Medicine;2024-06-24